仟源医药(300254) - 300254仟源医药投资者关系管理信息20250828

Market Expansion - As of June 2025, the company's smoking cessation drug, varenicline tartrate tablets, has entered over 100,000 retail stores in the OTC market, with a target of exceeding 140,000 stores by the end of 2025 and 250,000 stores by the end of 2026 [2][3] Market Capacity - The smoking cessation drug market in China has a significant potential, with over 300 million smokers, and the company aims to cover 50 million smokers over the next 10 years [2] User Demographics - The user demographic for varenicline tartrate tablets spans all age groups, with the highest proportion being male smokers in their 30s [3] Cost of Treatment - The estimated cost for each smoker using the varenicline tartrate tablets for a 3-month treatment course is no more than RMB 2,000 [3] Shareholding and Future Plans - The company acknowledges that its major shareholders have a relatively low holding percentage and plans to promote a stock issuance project to specific investors [3]